122 related articles for article (PubMed ID: 9162303)
1. Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials.
Loprinzi CL; Messing EM; O'Fallon JR; Poon MA; Love RR; Quella SK; Trump DL; Morton RF; Novotny P
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):371-4. PubMed ID: 9162303
[TBL] [Abstract][Full Text] [Related]
2. Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer.
Messing E; Kim KM; Sharkey F; Schultz M; Parnes H; Kim D; Saltzstein D; Wilding G
J Urol; 2006 Aug; 176(2):500-4. PubMed ID: 16813878
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO.
Moon RC; Kelloff GJ; Detrisac CJ; Steele VE; Thomas CF; Sigman CC
Anticancer Res; 1994; 14(1A):5-11. PubMed ID: 8166455
[TBL] [Abstract][Full Text] [Related]
4. Irreversible ototoxicity associated with difluoromethylornithine.
Lao CD; Backoff P; Shotland LI; McCarty D; Eaton T; Ondrey FG; Viner JL; Spechler SJ; Hawk ET; Brenner DE
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1250-2. PubMed ID: 15247138
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
6. Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
Sabichi AL; Lerner SP; Atkinson EN; Grossman HB; Caraway NP; Dinney CP; Penson DF; Matin S; Kamat A; Pisters LL; Lin DW; Katz RL; Brenner DE; Hemstreet GP; Wargo M; Bleyer A; Sanders WH; Clifford JL; Parnes HL; Lippman SM
Clin Cancer Res; 2008 Jan; 14(1):224-9. PubMed ID: 18172274
[TBL] [Abstract][Full Text] [Related]
7. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
8. Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Carbone PP; Pirsch JD; Thomas JP; Douglas JA; Verma AK; Larson PO; Snow S; Tutsch KD; Pauk D
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):657-61. PubMed ID: 11401916
[TBL] [Abstract][Full Text] [Related]
9. A prospective clinical trial of difluoromethylornithine (DFMO) in patients with resected superficial bladder cancer.
Loprinzi CL; Messing EM
J Cell Biochem Suppl; 1992; 16I():153-5. PubMed ID: 1305680
[TBL] [Abstract][Full Text] [Related]
10. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
12. 13-cis-retinoic acid in chemoprevention of superficial bladder cancer. The National Bladder Cancer Group.
Prout GR; Barton BA
J Cell Biochem Suppl; 1992; 16I():148-52. PubMed ID: 1305679
[TBL] [Abstract][Full Text] [Related]
13. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
14. A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer.
Love RR; Jacoby R; Newton MA; Tutsch KD; Simon K; Pomplun M; Verma AK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):989-92. PubMed ID: 9829706
[TBL] [Abstract][Full Text] [Related]
15. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
16. Delayed, reversible hearing loss caused by difluoromethylornithine (DFMO).
Doyle KJ
Laryngoscope; 2001 May; 111(5):781-5. PubMed ID: 11359155
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
18. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
19. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of alpha-difluoromethylornithine as a potential chemopreventive agent: tolerance to daily oral administration in humans.
Creaven PJ; Pendyala L; Petrelli NJ
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):243-7. PubMed ID: 8318877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]